Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
UBS $1.25 billion senior notes offering
The investment-grade notes are due 2028
SP Group Treasury GMTN update and $700 million notes offering
The notes are due 2029
BBVA $1 billion preferred securities offering
We advised BBVA on its offering of contingent convertible perpetual preferred securities
Toyota Motor Credit $2.6 billion notes offering
We advised Toyota Motor Credit on the SEC-registered notes offering
The Baldwin Group $935 million credit facilities financing
We advised the borrower on the refinancing and amendment
CRH $3 billion guaranteed notes offering
The investment-grade notes are due 2030, 2035 and 2055
iHeart comprehensive out-of-court debt restructuring
We advised an ad hoc group of noteholders and term loan lenders on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Veritas Technologies comprehensive debt recapitalization transaction
We advised an ad hoc group of term lenders and noteholders on the transaction